- Home
- » Tags
- » Bevacizumab
Top View
- Zydus Launches Ujvira (Trastuzumab Emtansine), a Breakthrough in Breast Cancer Treatment
- NCCN Guidelines for Patients Metastatic Breast Cancer
- MAHA) in Patients Treated with Avastin® (Bevacizumab) and Sunitinib Malate
- 125427Orig1s000
- Avastin, INN-Bevacizumab
- Antitumor Activity of Capecitabine and Bevacizumab Combination in a Human Estrogen Receptor-Negative Breast Adenocarcinoma Xenograft Model
- (INN) for Biological and Biotechnological Substances
- Phase II Trial of FOLFOX6, Bevacizumab, and Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- Gastric Cancers
- Correlation Between the Qualification for Bevacizumab Use and The
- Bevacizumab, Sunitinib: Osteonecrosis of the Jaw Venous Sclerosants
- Real-World Effectiveness of Post-Trastuzumab Emtansine
- Evolution of Escherichia Coli Expression System in Producing Antibody Recombinant Fragments
- Vectibix (Panitumumab) Is a Recombinant, Human Igg2 Kappa Monoclonal Antibody That Binds Specifically to the Human Epidermal Growth Factor Receptor (EGFR)
- SUTENT (Sunitinib Malate)
- DRUG NAME: Bevacizumab
- Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: a Decision Analysis
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
- Copyrighted Material
- Continuation of Bevacizumab Vs Cetuximab Plus Chemotherapy
- A Combination of Low-Dose Bevacizumab and Imatinib Enhances Vascular Normalisation Without Inducing Extracellular Matrix Deposition
- Continuing Cetuximab Vs Bevacizumab Plus Chemotherapy
- Breast Cancer (Recurrent Or Metastatic) Treatment Regimens
- Effect of First-Line Chemotherapy Combined with Cetuximab Or
- Efficacy and Safety of Combined Carboplatin, Paclitaxel, And
- Highlights in Metastatic Breast Cancer from the 2019 San Antonio Breast
- Nephrotoxicity of Anti-Angiogenic Therapies
- Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer ISSN 1366-5278 Feedback Your Views About This Report
- (Avastin®) and Bevacizumab Biosimilars
- Approval Letter for This Application
- Immunotherapy for Advanced Hepatocellular Carcinoma
- The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
- Antibody–Drug Conjugates for the Treatment of Breast Cancer
- Phase 1B Trial of Nintedanib in Combination with Bevacizumab in Patients with Advanced Solid Tumors
- Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis
- AVASTIN Prescribing Information
- Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
- Cetuximab, Bevacizumab and Panitumumab for the Treatment Of
- (INN) for Biological and Biotechnological Substances
- Vectibix® (Panitumumab)
- Does the Consensus Molecular Subtypes Classification Add to Selection of Precision Medicine in Patients with Metastatic Colorectal Cancer?
- A Phase I Trial of Glivec® Plus Mfolfox-Avastin®In Patients With
- Role of Novel Targeted Therapies in the Clinic
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2
- First-Line Atezolizumab Plus Bevacizumab Versus Sorafenib in Hepatocellular Carcinoma: a Cost-Effectiveness Analysis
- Assessment of the Evolution of Cancer Treatment Therapies
- Bevacizumab (Avastin®) (“Be Vuh SIZ Uh Mab”)
- Biosimilar Preferred Products Established For
- Clinical Study Report
- Phase 3 Results from Imbrave150 Ann-Lii Cheng,1 Shukui Qin,2 Masafumi Ikeda,3 Peter R
- AVASTIN (Bevacizumab)
- Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models